Benign Fibrohistiocytic Neoplasm — Variants & evidence

Benign Fibrohistiocytic Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items (2 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF F595L1
Vemurafenib	Histiocytoma	Predictive	D	Supports Resistance	—	submitted	EID4426 In an in vitro study, a Plat-E cell line expressing a BRAF F595L mutation was associated with resistance to vemurafenib treatment, as compared to Plat-E cells expressing vector, wild-type BRAF or BRAF… (full text at CIViC) PMID 26582644 · Kordes et al., 2016 · Open in CIViC	civic
BRAF V600E1
Vemurafenib	Histiocytoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID3789 A primary central nervous system (CNS)-histiocytic sarcoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with vemurafeni… (full text at CIViC) PMID 25209580 · Idbaih et al., 2014 · Open in CIViC	civic

Data updated 18 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.